After an earlier trial showed patients with elevated levels of a cardiac stress marker benefited from its cell therapy, the firm shifted focus to this subset.

On the heels of its acquisition by Ocuphire Pharma, Opus is planning next steps for its Leber congenital amaurosis type 5 ...

ACMG, NSGC, and others in the genetics community are monitoring whether the widely used online clinical genetics database ...

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

The biotech firm closed an oversubscribed Series C funding round, proceeds from which it will use to advance ATSN-201 and its ...

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Friday recommended that the National Health Service make AstraZeneca's AKT pathway inhibitor Truqap (capivasertib) with ...

NEW YORK – The US Food and Drug Administration on Thursday granted full approval to Bayer's TRK inhibitor Vitrakvi (larotrectinib) for treating adult and pediatric patients with previously treated ...

NEW YORK – Amylyx Pharmaceuticals announced this week that it has dosed the first amyotrophic lateral sclerosis (AML) patient with its investigational antisense oligonucleotide therapy (ASO), AMX0114, ...

Researchers shared data at ACC from BioCardia's initial Phase III cell therapy trial, which the firm stopped enrolling based ...